Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
A phase 1/2 trial of JDQ443, TNO155 and Tislelizumab in non-small-cell lung cancer and colorectal cancer, run by Novartis Pharmaceuticals, active and no longer recruiting.
Overview
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation is a phase 1/2 interventional study registered as NCT04699188 by Novartis Pharmaceuticals, with 344 participants enrolled, started 2021-02-24 and due to reach its primary completion in 2027-01-25. Interventions recorded: JDQ443, TNO155 and tislelizumab.
Similar pages
not linked directly; found by shared links- TrialStudy of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.
Shares JDQ443, Advanced Accelerator Applications (Novartis), Non-small-cell lung cancer and the tag pipeline.
- TrialPhase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
Shares Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
- TrialIntratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS
Shares Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
- TrialClinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
Shares Tislelizumab, Non-small-cell lung cancer and the tag pipeline.
- TrialPhase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
Shares Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
- TrialStudy of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
Shares Advanced Accelerator Applications (Novartis) and the tag pipeline.
- TrialRibociclib (LEE011) Rollover Study for Continued Access
Shares Advanced Accelerator Applications (Novartis) and the tag pipeline.
- TrialA Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer
Shares Advanced Accelerator Applications (Novartis) and the tag pipeline.